NASDAQ:GNCAGenocea Biosciences Stock Price, Forecast & News

$3.06

+0.25 (+8.90 %)

(As of 05/26/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.80

Now: $3.06▼

$3.40

50-Day Range

$1.66

MA: $2.22▼

$2.81

52-Week Range

$1.10

Now: $3.06▼

$11.28

Volume2.31 million shs

Average Volume366,782 shs

Market Capitalization$84.58 million

P/E RatioN/A

Dividend YieldN/A

Beta2.21

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Genocea Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.33, Genocea Biosciences has a potential upside of 433.8% from its current price of $3.06.
Amount of Analyst Coverage
Genocea Biosciences has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Genocea Biosciences has received 372 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Genocea Biosciences has received 294 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Genocea Biosciences has received 55.86% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote “Outperform” if you believe GNCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Genocea Biosciences does not currently pay a dividend.
Dividend Growth
Genocea Biosciences does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genocea Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.33% of the stock of Genocea Biosciences is held by insiders.
Percentage Held by Institutions
50.26% of the stock of Genocea Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Genocea Biosciences are expected to grow in the coming year, from ($1.56) to ($1.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Genocea Biosciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genocea Biosciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Genocea Biosciences has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GNCA

Previous Symbol

CUSIPN/A

CIK1457612

Webwww.genocea.com

Phone617-876-8191

Debt

Debt-to-Equity Ratio1.28

Current Ratio1.98

Quick Ratio1.98

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.45 per share

Price / Book6.80

Profitability

EPS (Most Recent Fiscal Year)($2.09)

Net Income$-38,950,000.00

Net MarginsN/A

Return on Equity-152.70%

Return on Assets-70.41%

Miscellaneous

Employees61

Outstanding Shares27,640,000

Market Cap$84.58 million

Next Earnings Date7/23/2020 (Estimated)

OptionableOptionable

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

How has Genocea Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GNCA stock has increased by 67.2% and is now trading at $3.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Genocea Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genocea Biosciences.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Genocea Biosciences.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) issued its quarterly earnings data on Thursday, April, 30th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.11. View Genocea Biosciences' earnings history.

What price target have analysts set for GNCA?

4 analysts have issued 12 month price objectives for Genocea Biosciences' shares. Their forecasts range from $7.00 to $32.00. On average, they anticipate Genocea Biosciences' share price to reach $16.33 in the next year. This suggests a possible upside of 433.8% from the stock's current price. View analysts' price targets for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:

1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (5/6/2020)
2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019)

Has Genocea Biosciences been receiving favorable news coverage?

Headlines about GNCA stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genocea Biosciences earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future. View the latest news aboutGenocea Biosciences.

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 128,700 shares, a drop of 43.7% from the April 30th total of 228,400 shares. Based on an average daily volume of 283,400 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.8% of the company's stock are short sold. View Genocea Biosciences' Current Options Chain.

Who are some of Genocea Biosciences' key competitors?

Some companies that are related to Genocea Biosciences include Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Tcr2 Therapeutics (TCRR), Gritstone Oncology (GRTS), ADMA Biologics (ADMA), Verona Pharma (TARA), Sutro Biopharma (STRO), Vaxart (VXRT), Axcella Health (AXLA), Pluristem Therapeutics (PSTI), GENFIT S A/ADR (GNFT), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE), Brainstorm Cell Therapeutics (BCLI) and Fennec Pharmaceuticals (FENC). View all competitors.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:

Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Who are Genocea Biosciences' major shareholders?

Genocea Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include NEA Management Company LLC (26.14%), FNY Investment Advisers LLC (1.09%), Bank of New York Mellon Corp (0.07%) and WINTON GROUP Ltd (0.06%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri and Peter W Sonsini. View institutional ownership trends for Genocea Biosciences.

Which major investors are buying Genocea Biosciences stock?

GNCA stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, FNY Investment Advisers LLC, Bank of New York Mellon Corp, and WINTON GROUP Ltd. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri, and Peter W Sonsini. View insider buying and selling activity for Genocea Biosciences.

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $3.06.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $84.58 million. The biotechnology company earns $-38,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is www.genocea.com.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff